Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Proteomics Group Focusing On Ways To Diagnosis Alzheimer's Disease

Executive Summary

Measuring protein differences for the diagnosis and treatment of Alzheimer's disease is among the projects currently being pursued by Roche's proteomics group.

You may also be interested in...



Relenza Prophylaxis Indication Withdrawn In EU; Pediatric Use Cleared In U.S.

Glaxo Wellcome's influenza medication Relenza for prevention of flu was withdrawn from the EU mutual recognition process so the company could resubmit the application with more data in elderly and high-risk patients, Glaxo said.

Relenza Prophylaxis Indication Withdrawn In EU; Pediatric Use Cleared In U.S.

Glaxo Wellcome's influenza medication Relenza for prevention of flu was withdrawn from the EU mutual recognition process so the company could resubmit the application with more data in elderly and high-risk patients, Glaxo said.

Roche Likes Its Critical Mass But Could Amass More; $2 Bil. R&D Will Do

Roche's restructuring and internal growth obviates the need for a merger, even with the recent loss of several late-phase clinical projects, CEO Franz Humer told the Roche 1999 annual earnings conference March 30 in Basel.

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel